Eli Lilly CEO Dave Ricks Talks Fighting Obesi...

Hatch CEO Ann Crady Weiss discusses the launch of its Hatch Sleep Clock, a contactless sleep tracker built to change sleep behavior rather than score it. She discusses other products from Hatch, the sleep tech market and more. She speaks with hosts Tim Stenovec and Kristine Aquin ...  Show more

David Booth, Dimensional Fund Advisors founder and chairman, discusses the theme of his new book "Stay Calm: Learn to Embrace Uncertainty in Investing and Life," and his historic $300 Million gift to the University of Kansas. He speaks with hosts Caroline Hepker and Judy Lagrou.S ...  Show more

Eli Lilly is the world's most valuable drug company, known for its blockbuster anti-obesity drugs that's transforming America. In an episode of "The David Rubenstein Show: Peer to Peer Conversations," CEO Dave Ricks talks about how the company will begin studies this year to see ...  Show more

Nicolai Tangen meets with David Ricks, CEO of Eli Lilly, for a discussion about the pharmaceutical giant's remarkable journey. At the forefront is Eli Lilly's breakthrough work with weight reduction drugs, which are showing promise far beyond their original ...

Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ...  Show more

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ...